Guided Therapeutics (GTHP) Short term Debt (2011 - 2024)

Guided Therapeutics (GTHP) posted Short term Debt of $1.1 million for Q3 2024, little changed sequentially from $1.1 million in Q2 2024.

Guided Therapeutics (GTHP) Short term Debt (2011 - 2024) Analysis & Trends

Guided Therapeutics has reported Short term Debt for 13 years, with the latest figure at $1.1 million in Q3 2024.

Quarterly Short term Debt changed N/A year-over-year to $1.1 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.1 million (changed N/A YoY) and the FY2022 annual result came in at $17000.0, down 80.68% from the prior year.
Short term Debt steadied at $1.1 million in Q3 2024 per GTHP's latest filing, from $1.1 million in the prior quarter.
Over five years, Short term Debt peaked at $1.1 million in Q2 2024 and troughed at $17000.0 in Q4 2022.
A 4-year average of $330454.5 and a median of $88000.0 in 2021 frame the typical range for Short term Debt.
The widest YoY moves for Short term Debt: up 2661.11% in 2022, down 84.74% in 2022.
Over 4 years, Short term Debt stood at $328000.0 in 2020, then sank by 73.17% to $88000.0 in 2021, then tumbled by 80.68% to $17000.0 in 2022, then surged by 6547.06% to $1.1 million in 2024.
According to Business Quant data, Short term Debt over the past three periods registered $1.1 million, $1.1 million, and $17000.0 for Q3 2024, Q2 2024, and Q4 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn
10	Guided Therapeutics	26.06 Mn	26.05 Mn	-

Download Data